CP
ABUS icon

CenterBook Partners’s Arbutus Biopharma ABUS Stock Holding History

CenterBook Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Buy
+445,151
New +$1.95M 0.11% 219

Other funds holding ABUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FCH
Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return
LWA
Ledgewood Wealth Advisors Exeter, New Hampshire $188M AUM 18.45% 1-Year Est. Return
CCA
Carrera Capital Advisors Troy, Michigan $675M AUM 17.92% 1-Year Est. Return

CenterBook Partners's ABUS Position: Q2 2026 in Review

CenterBook Partners opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 445,151 shares worth $2.14M. The stake represents 0.11% of the portfolio and ranks #219 among its holdings.

69 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • CenterBook Partners held 445,151 shares of Arbutus Biopharma worth $2.14M as of Q2 2026.
  • Arbutus Biopharma was a new CenterBook Partners position in Q2 2026.
  • Arbutus Biopharma made up 0.11% of CenterBook Partners's portfolio in Q2 2026, its #219 holding.
  • 69 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.